注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Bicycle Therapeutics plc 是一家总部位于英国的临床阶段生物制药公司。该公司正在开发一类药物,它称之为Bicycles,用于治疗现有疗法治疗不足的疾病。Bicycles是将通常与生物制剂相关的药理学与小分子的制造和药代动力学特性相结合的治疗方式。其候选产品 BT5528、BT8009和BT1718均为Bicycles毒素偶联物(BTC)。BT5528是第二代BTC,旨在靶向肝配蛋白A型受体2(EphA2)。BT8009是第二代BTC,旨在靶向Nectin-4,一种经过验证的肿瘤抗原。正在开发BT1718以靶向表达1型膜基质金属蛋白酶(MT1 MMP)的肿瘤。其候选产品BT7480和BT7455均为Bicycle肿瘤靶向免疫细胞激动剂。除了全资拥有的肿瘤产品组合外,公司还专注于其他治疗领域。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Charles Swanton | 50 | 2020 | Member of Scientific Advisory Board |
Jane Grogan | 55 | 2020 | Member of Scientific Advisory Board |
Geoffrey I. Shapiro | - | 2018 | Member of Scientific Advisory Board |
Garret A. FitzGerald | - | 2020 | Member of Scientific Advisory Board |
Pierre Legault | 62 | 2019 | Non-Executive Chairman |
Caetano Reis e Sousa | - | 2020 | Member of Scientific Advisory Board |
Keith Peters | 84 | 2018 | Chairman of Scientific Advisory Board |
Kevin Lee | 54 | 2015 | CEO & Executive Director |
Janice T. Bourque | 66 | 2019 | Independent Non-Executive Director |
Richard N. Kender | 67 | 2019 | Independent Non-Executive Director |
Gregory Paul Winter | 73 | - | Co-Founder & Non-Executive Director |
Jose-Carlos Gutierrez-Ramos | 62 | 2021 | Independent Non-Executive Director |
Stephen Sands | 67 | 2024 | Independent Director |
Felix James Baker | 55 | 2024 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核